Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of Tarceva (erlotinib) alone or intercalated with chemotherapy in EGFR-overexpressing advanced NSCLC
2006-005905-79Phase 2Completed
- Sponsor
- OSI Pharmaceuticals, Inc.
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of erlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by OSI Pharmaceuticals, Inc. Primary endpoint: Efficacy at 6 months. Started Jan 2007; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-005905-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005905-79.